U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C20H18FNO4
Molecular Weight 355.3596
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of VIDOFLUDIMUS

SMILES

COC1=CC=CC(=C1)C2=CC(F)=C(NC(=O)C3=C(CCC3)C(O)=O)C=C2

InChI

InChIKey=XPRDUGXOWVXZLL-UHFFFAOYSA-N
InChI=1S/C20H18FNO4/c1-26-14-5-2-4-12(10-14)13-8-9-18(17(21)11-13)22-19(23)15-6-3-7-16(15)20(24)25/h2,4-5,8-11H,3,6-7H2,1H3,(H,22,23)(H,24,25)

HIDE SMILES / InChI
Molecular Formula C20H18FNO4
Molecular Weight 355.3596
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including http://www.4sc.de/wp-content/uploads/Poster-Tokyo.pdf

Vidofludimus (SC12267; 4SC-101) is a novel oral immunomodulator inhibiting dihydroorotate dehydrogenase (DHODH) and the expression of proinflammatory cytokines including interleukin-17 (IL17A and IL17F) and interferon-gamma. This drug is in the clinical trial for the treatment of inflammatory bowel diseases and Rheumatoid arthritis.

Originator

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
 134.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Phase II
1132
Unknown

Approved Use

Unknown
Palliative
Phase II
1132
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
6.543 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/32361977
30 mg 1 times / day multiple, oral
dose: 30 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
VIDOFLUDIMUS plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
10.911 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/32361977
40 mg 1 times / day multiple, oral
dose: 40 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
VIDOFLUDIMUS plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
10.783 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/32361977
50 mg 1 times / day multiple, oral
dose: 50 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
VIDOFLUDIMUS plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
100.294 μg × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/32361977
30 mg 1 times / day multiple, oral
dose: 30 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
VIDOFLUDIMUS plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
158.686 μg × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/32361977
40 mg 1 times / day multiple, oral
dose: 40 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
VIDOFLUDIMUS plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
166.401 μg × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/32361977
50 mg 1 times / day multiple, oral
dose: 50 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
VIDOFLUDIMUS plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
30.414 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/32361977
30 mg 1 times / day multiple, oral
dose: 30 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
VIDOFLUDIMUS plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
28.566 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/32361977
40 mg 1 times / day multiple, oral
dose: 40 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
VIDOFLUDIMUS plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
29.805 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/32361977
50 mg 1 times / day multiple, oral
dose: 50 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
VIDOFLUDIMUS plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
1587
substrate
1037

inhibitor
1767
inhibitor
1852

OverviewOther

Other InhibitorOther SubstrateOther Inducer
UGT1A1
204

BCRP
699

URAT1
3

P-gp
1461
CYP2C8
693
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP2D6
1891
 inconclusive [IC50 26.837 uM]
CYP3A4
1925
 inconclusive [IC50 26.837 uM]
P-gp
1650
 inconclusive [IC50 8.1995 uM]
UGT1A1
254
 weak
BCRP
773
 yes [IC50 0.02 uM]
CYP2C9
1819
 yes [IC50 21.3174 uM]
URAT1
3
 yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP2C8
693
 major
CYP2C9
1037
 minor
Sourcing

Sourcing

Vendor/AggregatorIDURL
1PlusChem LLC
1P00FCHW
https://www.1pchem.com/search?query=1P00FCHW
AOBIOUS INC
AOB87354
http://aobious.com/aobious/search?search_query=AOB87354
Ambeed
A377932
http://www.ambeed.com/search/Search.html?keyword=A377932
ApexBio Technology
B4669
https://www.apexbt.com/catalogsearch/result/?q=B4669
AstaTech
40649
http://astatechinc.com/CPSResult.php?CRNO=40649
Axon MedChem
2377
https://www.axonmedchem.com/product/2377
BLD Pharm
BD630834
http://www.bldpharm.com/search/Search.html?keyword=BD630834
Cayman Chemical
18377
http://www.caymanchem.com/app/template/Product.vm/catalog/18377
Chem Scene
CS-3221
http://www.chemscene.com/goproductList/searchProductList?productObj=CS-3221
ChemShuttle
151967
https://www.chemshuttle.com/catalogsearch/result/?q=151967
Debye Scientific
DA-41592
https://www.debyesci.com/index.php?id=product&ext[cno]=DA-41592
Excenen
EX-A546
http://www.excenen.com/searchresultlist.php?id=EX-A546
KeyOrganics
AS-56375
http://www.keyorganicsinc.com/bionet/catalogsearch/result?q=AS-56375
Lab Network
LN01341996
https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01341996
MedChem Express
HY-14908
https://www.medchemexpress.com/search.html?q=HY-14908&ft=&fa=&fp=
MolPort
MolPort-039-193-851
https://www.molport.com/shop/molecule-link/MolPort-039-193-851
Molnova
M17579
https://www.molnova.com/en/serch-list.html?keywords=M17579
MuseChem
I004676
https://www.musechem.com/product/I004676.html
Selleck Chemicals
S7262
http://www.selleckchem.com/search.html?searchDTO.searchParam=S7262
ShangHai Biochempartner
BCP001567
http://www.biochempartner.com/search_BCP001567
ShangHai Biochempartner
BCP14555
http://www.biochempartner.com/search_BCP14555
TargetMol
T2601
https://www.targetmol.com/search?keyword=T2601
eMolecules
50282989
https://orderbb.emolecules.com/search/#?query=50282989
eNovation Chemicals
D501823
https://www.enovationchem.com/Products.asp?SEARCHTEXT=D501823&searchbtn.x=0&searchbtn.y=0
mcule
MCULE-1963512370
https://mcule.com/MCULE-1963512370/
PubMed

PubMed

TitleDatePubMed
New preclinical findings with vidofludimus.
2010 Jul
4SC-101, a novel immunosuppressive drug, inhibits IL-17 and attenuates colitis in two murine models of inflammatory bowel disease.
2010 Oct
Patents

Patents

20030203951
3
20060199856
3
20070027193
3

Sample Use Guides

In Vivo Use Guide
at a dose of 35 mg once daily
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment: Peripheral blood mononuclear cells (PBMCs) from healthy human donors were used to evaluate cellular proliferation and cytokine (IL-17, TNF-α) production. 4SC-101 (VIDOFLUDIMUS) is a potent inhibitor of human Dihydroorotate dehydrogenase (DHODH), inhibits lymphocyte proliferation, and uniquely blocks phytohemagglutinin-stimulated IL-17 production by lymphocytes.
Unknown
Substance Class Chemical
Created
by admin
on Sat Dec 16 02:15:49 UTC 2023
Edited
by admin
on Sat Dec 16 02:15:49 UTC 2023
Record UNII
8Y1PJ3VG81
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
VIDOFLUDIMUS
INN   WHO-DD  
INN  
Official Name English
SC-12267
Code English
vidofludimus [INN]
Common Name English
1-CYCLOPENTENE-1-CARBOXYLIC ACID, 2-(((3-FLUORO-3'-METHOXY(1,1'-BIPHENYL)-4-YL)AMINO)CARBONYL)-
Common Name English
NSC-717824
Code English
SC12267
Code English
4SC-101
Code English
IMU-838
Code English
Vidofludimus [WHO-DD]
Common Name English
Code System Code Type Description
FDA UNII
8Y1PJ3VG81
Created by admin on Sat Dec 16 02:15:49 UTC 2023 , Edited by admin on Sat Dec 16 02:15:49 UTC 2023
PRIMARY
NCI_THESAURUS
C152873
Created by admin on Sat Dec 16 02:15:49 UTC 2023 , Edited by admin on Sat Dec 16 02:15:49 UTC 2023
PRIMARY
CAS
717824-30-1
Created by admin on Sat Dec 16 02:15:49 UTC 2023 , Edited by admin on Sat Dec 16 02:15:49 UTC 2023
PRIMARY
INN
9315
Created by admin on Sat Dec 16 02:15:49 UTC 2023 , Edited by admin on Sat Dec 16 02:15:49 UTC 2023
PRIMARY
MESH
C553728
Created by admin on Sat Dec 16 02:15:49 UTC 2023 , Edited by admin on Sat Dec 16 02:15:49 UTC 2023
PRIMARY
PUBCHEM
9820008
Created by admin on Sat Dec 16 02:15:49 UTC 2023 , Edited by admin on Sat Dec 16 02:15:49 UTC 2023
PRIMARY
DRUG BANK
DB05125
Created by admin on Sat Dec 16 02:15:49 UTC 2023 , Edited by admin on Sat Dec 16 02:15:49 UTC 2023
PRIMARY
EPA CompTox
DTXSID50431325
Created by admin on Sat Dec 16 02:15:49 UTC 2023 , Edited by admin on Sat Dec 16 02:15:49 UTC 2023
PRIMARY
NSC
717824
Created by admin on Sat Dec 16 02:15:49 UTC 2023 , Edited by admin on Sat Dec 16 02:15:49 UTC 2023
PRIMARY
SMS_ID
100000184316
Created by admin on Sat Dec 16 02:15:49 UTC 2023 , Edited by admin on Sat Dec 16 02:15:49 UTC 2023
PRIMARY
Related Record Type Details
DIHYDROOROTATE DEHYDROGENASE (QUINONE), MITOCHONDRIAL
TARGET -> INHIBITOR
Structure of VIDOFLUDIMUS CALCIUM MONOHYDRATE
SALT/SOLVATE -> PARENT
Structure of VIDOFLUDIMUS CALCIUM ANHYDROUS
SALT/SOLVATE -> PARENT
Related Record Type Details
Structure of VIDOFLUDIMUS
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966